Abstract:BACKGROUND & OBJECTIVE:Chemotherapy constitutes one of the chief supplementary methods in the treatment of nasopharyngeal carcinoma (NPC). However, the appearance of drug resistance often causes failure of chemotherapy. For overcoming drug resistance, it is of great importance to screen drug-resistant associated genes so as to identify potential molecular targets. This study was designed to establish a drug-resistant cell line from a human nasopharyngeal carcinoma cell line CNE2, and to screen human nasopharyngeal carcinoma drug-resistant genes by a new strategy based on improved subtractive hybridization.METHODS:The drug-resistant cell line was established by a program of treating the human nasopharyngeal carcinoma cells CNE2 in the medium with repeated sharp high and then low but gradually increasing concentration of cisplatin. Drug sensitivity was measured by MTT assay. Fluorescence activated cell analysis(FACS) was employed for determining the concentration of fluorescence dye rhodamine 123 within the cells. Cell growth curve, doubling time, and cell morphology were measured and observed. The drug-resistant genes were screened by a new strategy of PCR-based subtractive hybridization. Sequencing and blast analysis were performed after the differentially expressed genes had been verified by reverse dot blotting. The result was further confirmed by RT-PCR.RESULTS:The resistance indexes of CNE2/DDP to cisplatin (DDP), 5-fluorouracil (5-FU), and vincristine (VCR) were 27.9, 227.9, and 55.5, respectively, indicating its multi-drug resistant property. FACS analysis showed that the concentration of rhodamine 123 was much lower in CNE2/DDP cells than in CNE2 cells (12.98 vs. 243.62). The CNE2/DDP cells appeared smaller, more regularly round, and longer doubling time (26 hours vs. 19 hours) than CNE2 cells. Six differentially expressed sequences were discovered using improved subtractive hybridization; all of them were found to be homologous to known genes after sequencing analysis. Three of them were highly expressed in CNE2/DDP cells. Among them, one sequence, which encodes a 79 amino acid protein,known as DC13 protein (DC13), was a function unknown gene which has certain relationship with malignancy. The other two sequences were ubiquitin C gene and NADH dehydrogenase subunit 2 (ND2) gene, respectively. The other three of the six sequences, whose expression were inhibited in CNE2/DDP cells, were cytochrome C oxidase subunit I(COX1), ribosomal protein L27(RPL27),and ribosomal protein S27 (RPS27) genes, respectively.CONCLUSION:A drug- resistant cell line CNE2/DDP, which showed a typical resistant phenotype to anti-cancer drugs was established. The PCR-based improved subtractive hybridization is an effective approach to identify differentially expressed genes. Many genes, both known and unknown, might contribute to the existence of drug-resistant phenotype, through increasing or decreasing their expression.

Studies on Comparative Genomic Hybridization between Multiple Types of Paclitaxel-resistant Nasopharyngeal Carcinoma Cells and the Parent Cell Lines

Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells

Establishment of a paclitaxel-resistant human nasopharyngeal carcinoma cell line and study of its mechanisms

[Differential expression of taxol resistance and taxol resistance reversal related genes in nasopharyngeal carcinoma by cDNA microarray].

[Synergistic interactions of TRAIL and paclitaxel on the nasopharyngeal carcinoma cell lines in vitro].

Genomic methylation profiling combined with gene expression microarray reveals the aberrant methylation mechanism involved in nasopharyngeal carcinoma taxol resistance.

[Sensitivity of Two Cell Lines with Acquired Resistance to Gefitinib to Several Chemotherapeutic Drugs].

[Analysis of First-Line Chemoresistance and Prediction of Chemo-Response in Non-Small Cell Lung Cancer by Comparative Genomic Hybridization].

Comparative genomic hybridization analysis of nasopharyngeal carcinoma cell lines

Dna Microarray Reveals Different Pathways Responding To Paclitaxel And Docetaxel In Non-Small Cell Lung Cancer Cell Line

Next Generation Deep Sequencing Identified a Novel Lncrna N375709 Associated with Paclitaxel Resistance in Nasopharyngeal Carcinoma

Exosome-Mediated Transfer of ALDH2 in Nasopharyngeal Carcinoma Cells Confers Increased Resistance to Paclitaxel Treatment

[Establishment of a Human Nasopharyngeal Carcinoma Drug-Resistant Cell Line CNE2/DDP and Screening of Drug-Resistant Genes].

MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.

[Role of Folate Receptor 1 in Paclitaxel-Resistance of Nasopharyngeal Carcinoma Cells].

ATP-binding Cassette B1 Gene Polymorphisms, Mrna Expression and Chemosensitivity to Paclitaxel in Non-Small Cell Lung Cancer Cells.

GPRC5A promotes paclitaxel resistance and glucose content in NSCLC

Metadherin-mediated Cell Proliferation and Paclitaxel Resistance in Nasopharyngeal Carcinoma

Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells

A Clinical Research of Paclitaxel or Docetaxel Combined with Cisplatin in Treating Advanced Nasopharyneal Carcinoma

Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells